Jul 25 |
Why Psyence Biomedical (PBM) Stock Is Skyrocketing
|
Jul 24 |
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
|
Jul 23 |
US home sales dip, Secret Service director resigns: Catalysts
|
Jul 4 |
Psyence Biomedical receives Nasdaq notification regarding minimum bid price deficiency
|
Jul 4 |
Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
|
May 17 |
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
|
Apr 16 |
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
|
Apr 8 |
Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
|
Mar 26 |
Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
|
Mar 18 |
Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
|